[Federal Register Volume 75, Number 40 (Tuesday, March 2, 2010)]
[Notices]
[Page 9422]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4195]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0001]
Tobacco Products Scientific Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Tobacco Products Scientific Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on March 30 and 31, 2010,
from 8:30 a.m. to 5 p.m.
Location: National Transportation Safety Board (NTSB) Conference
Center, 429 L'Enfant Plaza SW., Washington, DC 20594 (at Metro's
L'Enfant Plaza station; parking is limited and public transportation is
recommended.)
Contact Person: Cristi Stark, Office of Science, Center for Tobacco
Products, Food and Drug Administration, 9200 Corporate Blvd.,
Rockville, MD 20850, 240-276-3992, e-mail: [email protected] or
FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572
in the Washington, DC area), code 8732110002. Please call the
Information Line for up-to-date information on this meeting. A notice
in the Federal Register about last minute modifications that impact a
previously announced advisory committee meeting cannot always be
published quickly enough to provide timely notice. Therefore, you
should always check the agency's Web site and call the appropriate
advisory committee hot line/phone line to learn about possible
modifications before coming to the meeting.
Agenda: On March 30, 2010, the Tobacco Products Scientific Advisory
Committee will cover the following two topics: (Topic 1) Receive
presentations on the background and overview of the FDA Center for
Tobacco Products, the Family Smoking Prevention and Tobacco Control Act
(the Tobacco Control Act), and the Tobacco Products Scientific Advisory
Committee; and (Topic 2) receive presentations on and discuss the
published literature on menthol as it relates to the demographics of
users, preferential use by persons initiating tobacco use, the health
effects of menthol in cigarettes, the effects of menthol on addiction
and cessation, marketing and consumer perceptions about menthol
cigarettes, the sensory qualities of menthol cigarettes, and the
effects of menthol on how cigarettes are smoked. On March 31, 2010, the
Committee will continue the presentations and discussions of topic 2;
and also receive preliminary information about topics planned for
discussion at future meetings, including an action plan designed to
ensure the enforcement of restrictions required by the Tobacco Control
Act on the advertising and promotion of menthol and other cigarettes to
youth, and the establishment of a list of harmful and potentially
harmful tobacco product constituents, including smoke constituents.
These discussions are preliminary to the preparation of the Tobacco
Products Scientific Advisory Committee's required report to the
Secretary of Health and Human Services regarding the impact of use of
menthol in cigarettes on the public's health. A second meeting of the
Tobacco Products Scientific Advisory Committee, focusing on tobacco
industry research and documents related to menthol and cigarettes, is
planned for summer 2010.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written subissions may be made to the contact person on or before March
22, 2010. Oral presentations from the public will be scheduled between
approximately 9:30 a.m. and 10:30 a.m. on March 31, 2010. Those
desiring to make formal oral presentations should notify the contact
person and submit a brief statement of the general nature of the
evidence or arguments they wish to present, the names and addresses of
proposed participants, and an indication of the approximate time
requested to make their presentation on or before March 12, 2010. Time
allotted for each presentation may be limited. If the number of
registrants requesting to speak is greater than can be reasonably
accommodated during the scheduled open public hearing session, FDA may
conduct a lottery to determine the speakers for the scheduled open
public hearing session. The contact person will notify interested
persons regarding their request to speak by March 15, 2010.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Cristi Stark at
least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: February 24, 2010.
Joanne Less,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2010-4195 Filed 3-1-10; 8:45 am]
BILLING CODE 4160-01-S